FilingReader Intelligence

Huadong Medicine proposes dividend, inks key collaboration deals

April 21, 2025 at 07:54 AM UTCBy FilingReader AI

Huadong Medicine (SZSE:000963) announced a proposal for a cash dividend of CNY 1,017,364,687.84 for the year 2024. The decision, impacting shareholders with a payout of CNY 5.80 per 10 shares, will be put to vote at the annual general meeting. This announcement comes as Huadong prepares to vote for the next Board to take helm as well as other routine corporate actions. At the same time, the board has agreed for the company to continue key R&D and commercialization transactions. First, it has continued collaborations to advance pipeline and for related payments to Arcutis Biotherapeutics (USD 112.73M) and Kiniksa Pharmaceuticals (USD 105.70M). Second, an existing collaboration with Elevar Therapeautics is being wound down as a key cancer target has changed. Third, existing collaborations with Yuhan Stock Transfer and BioNova Pharmaceuticals Co. are continuing with royalty and fee schedule. The year 2025 will represent new efforts in the core therapeutic business.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SZSE:000963Shenzhen Stock Exchange

News Alerts

Get instant email alerts when Huadong Medicine publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →